Multiple Sclerosis Discovery Forum
  News and Future Directions
  Papers
  Forums
  Professional Resources
  Research Resources
MSGene - Gene overview of all published MS-association studies for IL2RA
Back Search Methods Disclaimer Credits
 Gene: IL2RA  (RP11-536K7.1; CD25; IDDM10; IL2R; TCGFR)  Entrez Gene    View on PDGene
 Protein: interleukin 2 receptor, alpha  (Interleukin-2 receptor; interleukin 2 receptor, alpha chain)  ProteinLink
 Chromosome: 10   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 25 November 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      MS Cases Normal Controls  
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
Akkad, 2009
Germany CL  4  (detail)  1319
(68%)
P31.4
(-)
-908
(47%)
46.7
(-)
Positive
Alcina, 2009
Spain CL  8  (detail)  798
(68%)
P-36
(-)
927
(59%)
38
(-)
Positive
ANZgene, 2009
Overlaps with
IMSGC, 2008 (GWAS)
CL,PO  1  (detail)  1618
(72%)
O/M34.1
(7-67)
-3413
(-)
-n.a.
ANZgene, 2009
Australia, New Zealand CL  1  (detail)  2256
(78%)
O/M34.5
(4-73)
-2310
(-)
-Positive
Aulchenko, 2008
Netherlands (GWAS) CL  1  (detail)  45
(-)
O/M--195
(-)
-Negative
Baranzini, 2008
USA, Netherlands, Switzerland (GWAS) CL  4  (detail)  978
(67%)
MD1&234
(11-61)
47
(21-69)
883
(66%)
46
(21-69)
Negative
Cavanillas, 2010
Overlaps with
Alcina, 2009
CL  3  (detail)  771
(69%)
P-29
(15-71)
759
(68%)
-Positive
Cavanillas, 2010
Spain (I) CL  3  (detail)  430
(65%)
P-29
(16-79)
550
(-)
-Positive
D'Netto, 2009
Canada CL  2  (detail)  43
(-)
U--182
(-)
-Negative
Hoppenbrouwers, 2008
Overlaps with
Aulchenko, 2008
CL  2  (detail)  46
(72%)
P33 + 11
(-)
-194
(-)
-n.a.
Hoppenbrouwers, 2009
Overlaps with
Aulchenko, 2008
CL  1  (detail)  45
(-)
O/M--195
(-)
-n.a.
Hoppenbrouwers, 2009
Netherlands (outbred) CL  2  (detail)  490
(-)
O/M--426
(-)
-Trend
IMSGC, 2007
Overlaps with
IMSGC, 2008 (UK)
CL  2  (detail)  928
(73%)
MD1&232.6
(13-60)
45.1
(17-79)
1475
(-)
-n.a.
IMSGC, 2007
Overlaps with
IMSGC, 2008 (USA)
CL  2  (detail)  1394
(73%)
MD1&233.1
(3-69)
45.4
(18-74)
1512
(-)
-n.a.
IMSGC, 2007
Overlaps with
IMSGC, 2008 (USA, UK)
CL,PO  3  (detail)  931
(75%)
MD1&227.8
(10-51)
38.6
(17-59)
2431
(-)
-n.a.
IMSGC, 2008
Overlaps with
Sanna, 2010
CL  2  (detail)  909
(-)
U--576
(-)
-Positive
IMSGC, 2008
Australia CL  2  (detail)  472
(-)
U--424
(-)
-Positive
IMSGC, 2008
Belgium CL  2  (detail)  405
(-)
U--462
(-)
-Negative
IMSGC, 2008
Denmark CL  2  (detail)  504
(-)
U--541
(-)
-Positive
IMSGC, 2008
Finland CL  2  (detail)  561
(-)
U--1017
(-)
-Positive
IMSGC, 2008
Germany CL  2  (detail)  206
(-)
U--605
(-)
-Positive
IMSGC, 2008
UK (Northern Ireland) CL  2  (detail)  683
(-)
U--532
(-)
-Positive
IMSGC, 2008
Italy CL  2  (detail)  863
(-)
U--775
(-)
-Negative
IMSGC, 2008
Norway CL  2  (detail)  738
(-)
U--1027
(-)
-Positive
IMSGC, 2008
Spain CL  2  (detail)  815
(-)
U--786
(-)
-Positive
IMSGC, 2008
Sweden CL  2  (detail)  1100
(-)
U--1251
(-)
-Negative
IMSGC, 2008
UK CL  2  (detail)  2323
(-)
U--2960
(-)
-Positive
IMSGC, 2008
USA CL  2  (detail)  1394
(-)
U--2466
(-)
-Positive
IMSGC, 2008
Overlaps with
Hoppenbrouwers, 2009 (Netherlands)
CL  2  (detail)  46
(-)
U--194
(-)
-n.a.
IMSGC, 2011
Europe, USA, Australia, New Zealand (WTCCC2-GWAS) CL,PO  2  (detail)  9722
(-)
U32.3
(-)
44.8
(-)
17376
(-)
-Positive
IMSGC, 2011
Netherlands (GeneMSA-GWAS) CL  2  (detail)  230
(74%)
U33
(-)
46
(-)
232
(-)
-Positive
IMSGC, 2011
USA (GeneMSA-GWAS) CL  2  (detail)  486
(76%)
U33
(-)
48
(-)
431
(-)
-Positive
IMSGC, 2011
Switzerland (GeneMSA-GWAS) CL  2  (detail)  253
(74%)
U33
(-)
45
(-)
208
(-)
-Positive
IMSGC, 2011
Australia, New Zealand (ANZ-GWAS) CL  2  (detail)  1618
(72%)
U34
(-)
-1988
(-)
-Positive
IMSGC, 2011
USA (BWH-GWAS) CL  2  (detail)  973
(72%)
U33
(-)
47
(-)
2952
(-)
-Positive
IMSGC, 2011
UK, USA (IMSGC2007-GWAS) CL,PO  2  (detail)  795
(76%)
U28
(-)
41
(-)
1679
(-)
-Positive
Maier, 2009
Overlaps with
IMSGC, 2008 (USA, UK)
CL  3  (detail)  2420
(-)
MD1--9407
(-)
-Positive
Matesanz, 2007
Overlaps with
Alcina, 2009
CL  3  (detail)  346
(-)
P--413
(-)
-Positive
Mkhikian, 2011
USA (I) CL  1  (detail)  1201
(-)
MD1--1493
(-)
-Positive
Mkhikian, 2011
USA (II) CL  1  (detail)  2080
(-)
U--7060
(-)
-Positive
Perera, 2009
Overlaps with
ANZgene, 2009 (GWAS)
CL  4  (detail)  1146
(-)
O/M--1309
(-)
-Positive
Rubio, 2008
Overlaps with
ANZgene, 2009 (GWAS)
CL  2  (detail)  1146
(75%)
O/M32
(7-67)
-1309
(-)
-Positive
Sanna, 2010
Italy-Sardinia (GWAS) CL  1  (detail)  882
(-)
MD1--872
(-)
-Positive
Weber, 2008
Overlaps with
IMSGC, 2008 (Germany)
CL  2  (detail)  206
(63%)
O/M-37.8
(19-59)
605
(-)
-n.a.
 African Descent
Johnson, 2009
USA CL  1  (detail)  918
(79%)
MD1--656
(71%)
-Negative
 Other/Mixed
Matiello, 2011
USA PO  2  (detail)  220
(-)
U--442
(-)
-Negative
Pandit, 2010
India CL  1  (detail)  197
(48%)
MD130 + 5.6
(-)
35.4 + 3.2
(-)
197
(49%)
31.2 + 4.4
(-)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds  
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
D'Netto, 2009
Overlaps with
D'Netto, 2009 (CC)
 2  (detail)  43211
(-)
U----n.a.
Hoppenbrouwers, 2009
Canada  2  (detail)   1318
(-)
O/M--1507
(-)
-Positive
IMSGC, 2007
Overlaps with
IMSGC, 2008 (UK)
 2  (detail)  380380
(75%)
MD1&227.4
(10-53)
37.4
(17-58)
--n.a.
IMSGC, 2007
Overlaps with
IMSGC, 2008 (USA)
 2  (detail)  229229
(79%)
MD1&231.1
(9-51)
39.4
(19-58)
--n.a.
IMSGC, 2007
Overlaps with
IMSGC, 2007 (UK-GWAS, CC)
 2  (detail)  453453
(75%)
MD1&226.5
(10-48)
38.2
(19-59)
--Positive
IMSGC, 2007
Overlaps with
IMSGC, 2007 (USA-GWAS, CC)
 2  (detail)  478478
(74%)
MD1&229
(11-51)
39
(17-57)
--Positive
IMSGC, 2008
Belgium  2  (detail)  114-U----Negative
IMSGC, 2008
Finland  2  (detail)  254-U----Positive
IMSGC, 2008
France  2  (detail)  540-U----Positive
IMSGC, 2008
UK  2  (detail)  833-U----Positive
IMSGC, 2008
USA  2  (detail)  707-U----Positive
IMSGC, 2008
Italy (Sardinia)  2  (detail)  363-U----Negative
Maier, 2009
Overlaps with
IMSGC, 2008 (USA, UK)
 3  (detail)  1282-MD1----Positive
Ramagopalan, 2009
Canada  1  (detail)  6001193
(-)
U--1553
(-)
-Positive
Weber, 2008
Overlaps with
IMSGC, 2008 (France)
 2  (detail)  540540
(70%)
O/M26.5
(9-47)
41.7
(19-67)
1080
(50%)
-n.a.
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine MS diagnosis ->  "P" (Poser criteria, 1983), "MD1" (McDonald criteria, 2001), "MD2" (revised McDonald criteria, 2005), "MD1&2" (McDonald criteria, 2001 and 2005), "O/M" (other/mixed), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
Print this page
Email this page
MSDF RSS

Text size
Share & Bookmark
MSGene Recent Updates
MSGene Top Results
Top Results Details
1. HLA-DRB1
2. IL2RA
3. IL7R
4. TAGAP
5. CLEC16A
6. EVI5
7. GWA_16q24.1
8. GWA_5p13.1
9. TTC34
10. AHI1   
[see more]
MSGene Stats
Studies: 789
Genes: 809
Polymorphisms: 2907
Meta-analyses: 324
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
Copyright © 2017 Biomedical Research Forum LLC Disclaimer Copyright